Last Updated: August 9, 2026

CLINICAL TRIALS PROFILE FOR DURAPREP


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DURAPREP

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00739583 ↗ Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions Completed Johns Hopkins University Phase 4 2008-08-01 Skin preparation solutions are used to clean the skin of the patient before surgery to decrease the rate of infection. This is particularly important for hip replacement to reduce the risk of prosthetic joint infection. The use of a mark on the skin for site identification has become the standard of care to decrease wrong site surgery. The Joint Commission has mandated site identification as part of the surgical "time-out". This procedure is also mandated by hospital policy. Preliminary work on cadaveric skin shows that the type of skin preparation can erase the mark used for surgical site identification. Erasure of the mark presents the surgeon with difficulty in performing the site identification. Any error or lack of visualization of the site marking could lead to catastrophic wrong site surgery. The investigators hypothesis is that chlorhexidine based skin preparation solutions erase site marking in comparison to iodine based skin preparation solutions. The investigators intend to prospectively study twenty patients undergoing total hip arthroplasty. Patients will be randomized to either a chlorhexidine based or an iodine based skin preparation solution. These solutions are both the current gold standard of clinical care. No differences have been shown in infection rates for total hip arthroplasty between these solutions. The site marking will be performed by the same surgeon in a standardized manner. The site marking will include the surgeon's three initials as per usual routine. Underneath the initials three random initials will be placed with a horizontal line drawn underneath. The preparation of the skin will be performed according to the manufacturer's specifications. Digital photographs will be taken of the skin marking after skin preparation. Photographs of the three random initials will be de-identified and placed in a "Powerpoint" presentation form. Ten orthopaedic surgeons will then read the site markings to identify the random initials and to tell whether the mark looks appropriate to perform a surgical timeout. The horizontal line will be digitally analyzed using Adobe Photoshop to quantitatively measure blackness of the mark.
NCT00829023 ↗ Efficacy of Surgical Preparation Solutions in Shoulder Surgery Completed CareFusion N/A 2007-06-01 The purpose of the present study was to examine the native bacteria around the shoulder and determine the efficacy of three different surgical skin-preparation solutions on the eradication of bacteria from the shoulder.
NCT00829023 ↗ Efficacy of Surgical Preparation Solutions in Shoulder Surgery Completed Northwestern University N/A 2007-06-01 The purpose of the present study was to examine the native bacteria around the shoulder and determine the efficacy of three different surgical skin-preparation solutions on the eradication of bacteria from the shoulder.
NCT01233050 ↗ Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery Completed 3M N/A 2010-12-01 Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
NCT01233050 ↗ Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery Completed University of Pennsylvania N/A 2010-12-01 Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
NCT01290978 ↗ Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin Completed Cyberderm Inc. Phase 4 2010-02-01 The purpose of this study is to find out if presurgical antiseptic preparations affect how well surgical drapes adhere to skin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DURAPREP

Condition Name

Condition Name for DURAPREP
Intervention Trials
Surgical Site Infection 2
Blood Loss 1
Pelvis; Fracture 1
Closed Lower Extremity Fracture 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DURAPREP
Intervention Trials
Surgical Wound Infection 3
Hemorrhage 1
Hip Fractures 1
Fractures, Open 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DURAPREP

Trials by Country

Trials by Country for DURAPREP
Location Trials
United States 23
Canada 2
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DURAPREP
Location Trials
Pennsylvania 3
California 2
Ohio 2
Maryland 2
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DURAPREP

Clinical Trial Phase

Clinical Trial Phase for DURAPREP
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DURAPREP
Clinical Trial Phase Trials
Completed 6
Unknown status 1
Enrolling by invitation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DURAPREP

Sponsor Name

Sponsor Name for DURAPREP
Sponsor Trials
3M 2
University of Pennsylvania 1
University of California, San Diego 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DURAPREP
Sponsor Trials
Other 12
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Duraprep Clinical Trials Update, Market Analysis and 2026–2036 Forecast

Last updated: July 28, 2026

Executive summary: Duraprep’s public clinical-trial footprint and market economics cannot be analyzed from the information provided. No drug-identifying details (active ingredient, dosage form, sponsor, FDA application type, or markets served) are included, so clinical development timelines, trial status, regulatory posture, and revenue projections cannot be produced accurately.

What is Duraprep (active ingredient) and what indication is it in?

Answer: Not determinable from the provided input.

Which Duraprep brand is this in FDA/EMA records?

Answer: Not determinable from the provided input.

Is Duraprep a prescription drug, OTC product, or medical device?

Answer: Not determinable from the provided input.

Does Duraprep have more than one formulation (solution, kit, powder, etc.)?

Answer: Not determinable from the provided input.

What clinical trials exist for Duraprep and what phase is it in now?

Answer: Not determinable from the provided input.

How many Duraprep trials are recruiting, active not recruiting, or completed?

Answer: Not determinable from the provided input.

What endpoints are used (overall survival, ORR, HbA1c, FEV1, safety, PK/PD)?

Answer: Not determinable from the provided input.

Key trial identifiers (NCT numbers, sponsor, sites, start/end dates)

Answer: Not determinable from the provided input.

What is the latest Duraprep clinical results update (readouts, publications, conference abstracts)?

Answer: Not determinable from the provided input.

What were the reported efficacy and safety outcomes?

Answer: Not determinable from the provided input.

Was Duraprep advanced after interim analysis?

Answer: Not determinable from the provided input.

Any dose-ranging or formulation changes tied to readouts?

Answer: Not determinable from the provided input.

When does Duraprep lose exclusivity, and what patents block generic or biosimilar entry?

Answer: Not determinable from the provided input.

What Orange Book patents and exclusivities apply to Duraprep?

Answer: Not determinable from the provided input.

What is the likelihood of Paragraph IV filings against Duraprep?

Answer: Not determinable from the provided input.

Is there any patent litigation related to Duraprep (including settlements)?

Answer: Not determinable from the provided input.

What is the FDA regulatory status of Duraprep (IND, NDA, BLA) and what is the next milestone?

Answer: Not determinable from the provided input.

What FDA pathway does Duraprep use (505(b)(2), 505(j), 351(a), priority review)?

Answer: Not determinable from the provided input.

Has Duraprep received FDA approval or is it still investigational?

Answer: Not determinable from the provided input.

What are the FDA review and launch timing implications?

Answer: Not determinable from the provided input.

How big is the Duraprep market today, and which geographies drive revenue?

Answer: Not determinable from the provided input.

TAM/SAM/SOM framing for Duraprep by indication and geography

Answer: Not determinable from the provided input.

Current competitors and substitution pressure

Answer: Not determinable from the provided input.

Pricing and reimbursement drivers

Answer: Not determinable from the provided input.

Duraprep sales forecast 2026–2036: what revenue range is plausible and why?

Answer: Not determinable from the provided input.

Forecast model inputs typically required (incidence, uptake curves, persistence, channel mix)

Answer: Not determinable from the provided input.

Base case vs upside vs downside scenarios

Answer: Not determinable from the provided input.

Sensitivities: time to approval, label expansion, payer restrictions

Answer: Not determinable from the provided input.

How does Duraprep compare with competing therapies (efficacy, safety, dosing, delivery system)?

Answer: Not determinable from the provided input.

Head-to-head availability and real-world evidence gaps

Answer: Not determinable from the provided input.

Formulary positioning and line-of-therapy placement

Answer: Not determinable from the provided input.

What is the competitive landscape for Duraprep: who is developing alternatives and how fast?

Answer: Not determinable from the provided input.

Active pipeline substitutes (mechanism class, phase, expected readouts)

Answer: Not determinable from the provided input.

Biosimilar and generic threat assessment

Answer: Not determinable from the provided input.

What generic entry risks exist for Duraprep and when could the first generic launch occur?

Answer: Not determinable from the provided input.

Paragraph IV triggers tied to exclusivities and patent expiry

Answer: Not determinable from the provided input.

Manufacturing/IP barriers (process, polymorph, formulation, method-of-use)

Answer: Not determinable from the provided input.

Key Takeaways

  • Duraprep cannot be assessed for clinical development status, regulatory posture, IP risk, or market outlook without drug-identifying information.
  • No defensible timeline, revenue forecast, competitor set, or litigation/patent pathway can be produced from the provided input.

FAQs

  1. How can I verify which Duraprep product is listed in the Orange Book?
  2. What clinical-trial registries typically capture Duraprep’s Phase 2/3 studies?
  3. What indicators suggest Duraprep approval odds before Phase 3 readouts?
  4. How do formulation patents change generic launch timelines for drugs like Duraprep?
  5. Which payer decisions most affect Duraprep uptake after launch?

References

No sources cited because no drug-identifying information was provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.